A recent study conducted at Oregon State University has provided new insight into a chemical process associated with Alzheimer’s disease, offering a potential pathway for improving future drug development. A scientist from the university, working alongside a team of undergraduate researchers, examined how molecular interactions linked to the disease occur in real time. By observing these reactions as they happened in a laboratory environment, the researchers were able to gain a clearer understanding of how certain chemical processes contribute to the progression of the condition. Their work aims to deepen scientific knowledge about the molecular behaviour behind Alzheimer’s while helping guide the design of more effective treatments in the future.
The team employed a specialised molecule-measuring technique that allowed them to closely observe how particular metal ions influence proteins connected with Alzheimer’s. These metals can trigger a process in which proteins begin to clump together, forming structures that interfere with the brain’s communication pathways. In the laboratory experiments, the scientists monitored how these metals interacted with amyloid-beta proteins, the substances widely associated with the development of Alzheimer’s-related damage in the brain. Being able to watch the process unfold moment by moment allowed the researchers to capture details that had previously remained difficult to observe in conventional experiments.
The study was led by Marilyn Rampersad Mackiewicz, an associate professor of chemistry in the university’s College of Science. Her research group focused on analysing both the formation of protein clusters and the ways certain molecules might interfere with that process. During their experiments, the team observed how compounds known as chelators could interrupt or even reverse the clumping of proteins. The findings, published in the scientific journal ACS Omega, suggest that observing these reactions in real time could provide researchers with new ways to evaluate potential therapeutic approaches.
Alzheimer’s disease remains the most common form of dementia, a chronic neurological condition characterised by declining cognitive ability and memory loss. The disease affects millions of people worldwide, particularly older adults, and has a significant emotional and social impact on families and caregivers. In individuals with Alzheimer’s, clusters of amyloid-beta proteins accumulate in the brain and disrupt communication between nerve cells. Although certain metals are essential for normal brain function, an imbalance in their concentration can contribute to these harmful protein aggregations, worsening the disruption of neural pathways.
In their experiments, the researchers examined how chelators—molecules that bind tightly to metal ions—interacted with these metals during the aggregation process. Using a method called fluorescence anisotropy, the team found that one chelator successfully captured metal ions but did so indiscriminately, binding to several types rather than focusing only on those linked to harmful protein clumping. Another chelator, however, showed a stronger ability to selectively target copper ions, which are believed to play an important role in triggering amyloid-beta aggregation. Observing these differences helped the researchers understand how specific molecular properties can influence the success of potential treatments.
The research also highlighted the value of studying chemical interactions as they occur rather than only examining the outcome of an experiment. By measuring the reactions second by second, the scientists were able to determine not just whether a molecule disrupted protein aggregation, but precisely how and when the disruption occurred. The team emphasised that although therapies based on these discoveries remain years away, the ability to observe and quantify these processes offers an important step forward. Future research will involve testing the findings in more complex biological environments, including cellular models and preclinical studies, in order to refine further strategies for designing treatments that may one day help counteract the damage caused by Alzheimer’s disease.
More information: Alyssa N. Schroeder et al, Selective Reversal of Cu-Amyloid Aggregation Monitored in Real Time by Fluorescence Anisotropy: Ni-Bme-Dach vs EDTA Benchmarks, ACS Omega. DOI: 10.1021/acsomega.5c11345
Journal information: ACS Omega Provided by Oregon State University
